RAC 4.32% $1.55 race oncology ltd

Ann: Appendix 4E & Annual Report, page-27

  1. 2,710 Posts.
    lightbulb Created with Sketch. 2824
    there is concern that Dexrazoxane reduces the efficacy of the cancer treatment, albeit cardio protective.

    On the flip side Zantrene is cardio protective, anti cancer as a single agent and synergises with Doxo. Not only Anthracyclines but also Proteasome inhibitors e.g. Krypolis.

    There are a few other cardio protective anti cancer treatments, either off patent so won’t be pursued or in research phases so many years behind Race.

    Thus Race is maintaining a first-in-class best-in-class advantage.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.55
Change
-0.070(4.32%)
Mkt cap ! $264.0M
Open High Low Value Volume
$1.62 $1.65 $1.54 $145.6K 91.60K

Buyers (Bids)

No. Vol. Price($)
2 5700 $1.55
 

Sellers (Offers)

Price($) Vol. No.
$1.59 296 1
View Market Depth
Last trade - 16.10pm 31/07/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.